Program
Program
Day 2: From innovation to implementation
Day 2: From innovation to implementation
The second day will focus on how science translates into practice. The focus will be on international experiences, regulatory frameworks, and a discussion on what the next steps are in Estonia.
Simultaneous interpretation into English will be provided for all presentations delivered in Estonian.
09:30–09:35
·
Gathering and morning coffee
09:35–10:20
Psychedelic Therapy - effects, neuromechanisms, and clinical implementation routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
09:35–10:20
Psychedelic Therapy - effects, neuromechanisms, and clinical implementation routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
09:35–10:20
Psychedelic Therapy - effects, neuromechanisms, and clinical implementation routes
This talk focuses on how psychedelic therapies such as psilocybin, DMT and ketamine can be integrated into public healthcare systems. Drawing on research and clinical programmes within the UK National Health Service (NHS), it explores practical models for implementation, alongside the latest findings on the therapeutic mechanisms and clinical effects of these treatments.
Dr. David Erritzoe, MD, PhD, MRCPsych
Clinical Associate Professor in Psychopharmacology and Psychiatry, Director of the Centre for Psychedelic Research & CIPPRes Clinic (Imperial College London)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim) Medical Director (OVID Clinic Berlin)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim) Medical Director (OVID Clinic Berlin)
10:20–11:05
From Clinical Evidence to Compassionate Use: Psilocybin Therapy for Treatment-Resistant Depression in Germany
This talk presents key findings from the largest academically initiated clinical trial of psilocybin to date, involving 144 patients with treatment-resistant depression. It explores how the study led to the European Union’s first compassionate use programme for a psychedelic, approved in Germany in 2025, and discusses the challenges and early experiences of translating clinical evidence into real-world practice.
Prof. Dr. med. Gerhard Gründer
Professor of Psychiatry and Head of the Department of Molecular Neuroimaging (Central Institute of Mental Health in Mannheim) Medical Director (OVID Clinic Berlin)
11:05–11:35
·
coffee break
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken) Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken) Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
11:35–12:20
National Implementation of Ketamine Treatment for Depression in Norway
In the Fall of 2025, Norway became the first country in the world to reimburse racemic ketamine for depression on a national level. This is the story of how and why it happened, and what other countries can learn from the process of building the infrastructure for psychedelic-assisted therapies.
Lowan Stewart, MD
Medical Director (Axonklinikken) Medical Research Advisor (PsykForsk, DPS Nordre Østfold)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich) Postdoctoral researcher (University of Zurich)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich) Postdoctoral researcher (University of Zurich)
12.20-13.05
The Swiss Special Access Program for Psychedelic-Assisted Therapy: Clinical Practice, Challenges, and Future Perspectives
This session explores Switzerland’s pioneering limited medical use programme for psychedelic-assisted therapy, including LSD, psilocybin and MDMA. It examines the regulatory framework, clinical experience, patient selection and ethical considerations, as well as current developments and future challenges for policy and practice.
Helena Aicher, PhD
Psychotherapist (Psychiatric Clinic of the University of Zurich) Postdoctoral researcher (University of Zurich)
13:05–14:05
·
lunch break
14:05–14:50
TBA
Tadeusz Hawrot
Founder and CEO (PAREA)
14:05–14:50
TBA
Tadeusz Hawrot
Founder and CEO (PAREA)
14:05–14:50
TBA
Tadeusz Hawrot
Founder and CEO (PAREA)
14:50–15:35
Panel discussion
TBA
14:50–15:35
Panel discussion
TBA
14:50–15:35
Vestlusring
TBA
15:35–15:45
·
closing remarks
13:20–14:20
·
closing remarks
15:35–15:45
·
closing remarks
15:45–16:30
·
networking
13:20–14:20
·
networking
15:45–16:30
·
networking
TAIP Foundation reserves the right to make changes to the programme.
Standard tickets are now on sale. Prices valid until September 7.
Sihtasutus Teraapia Arenduseks ja Innovatsiooniks Psühhedeelikumidega
info@sataip.ee